Edition:
United Kingdom

Michael Erman

Cost of blood pressure drug surges in U.S. after recall

16 Oct 2018

NEW YORK Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States in September, following a recall of much of the drug's supply.

CORRECTED-(OFFICIAL)-UPDATE 3-FDA halts imports from China's Huahai Chuannan plant

10 Oct 2018

SHANGHAI/NEW YORK, Sept 28 The U.S. Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients produced at China's Zhejiang Huahai Pharmaceuticals Chuannan factory, after a recall of one of its drugs that contained a probable carcinogen.

FDA halts imports from China's Huahai after heart drug recall

28 Sep 2018

SHANGHAI/NEW YORK The U.S. Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients produced by China's Zhejiang Huahai Pharmaceuticals, after a recall of one of its drugs that contained a probable carcinogen.

U.S. FDA approves Lilly migraine drug; price same as rivals

28 Sep 2018

NEW YORK Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration approved its migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.

U.S. FDA approves Lilly migraine drug; price same as rivals

28 Sep 2018

NEW YORK, Sept 27 Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration approved its migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.

Merck's Frazier to remain CEO of the U.S. drugmaker beyond 2019

26 Sep 2018

Merck & Co Inc Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEOs to retire at the age of 65.

Allergan says revenue from aesthetics unit may double by 2025

14 Sep 2018

NEW YORK Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

Insurance tactic drags down U.S. drug prices in second quarter: analyst

04 Sep 2018

NEW YORK U.S. drug prices fell again in the second quarter, likely due to a new tactic insurers are using to limit financial assistance drugmakers provide directly to consumers, according to research firm Sector and Sovereign Research (SSR).

Insurance tactic drags down U.S. drug prices in 2nd quarter -analyst

04 Sep 2018

NEW YORK, Sept 4 U.S. drug prices fell again in the second quarter, likely due to a new tactic insurers are using to limit financial assistance drugmakers provide directly to consumers, according to research firm Sector and Sovereign Research (SSR).

Europe ready to cash in on cheap copies of AbbVie biotech drug

29 Aug 2018

LONDON/NEW YORK U.S. drugmaker AbbVie ABBV.N faces a crunch moment in Europe in mid-October when less-expensive copies of its $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – hit the market.

World News